Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 3, 2009 Rich Smith	This Just In: Upgrades and Downgrades Quality Systems gets one upgrade and one downgrade.
The Motley Fool September 16, 2009 Rich Smith	This Just In: Upgrades and Downgrades Everybody loves eBay.
The Motley Fool July 6, 2010 Rich Smith	This Just In: Upgrades and Downgrades Piper says Applied Materials entry into solar has not gone well in the thin film solar market.
The Motley Fool January 22, 2010 Rich Smith	This Just In: Upgrades and Downgrades Even as Jesup & Lamont upped its 2010 earnings estimate, the analyst pulled its "buy" rating on Starbucks and downgraded the stock to "hold."
The Motley Fool December 17, 2009 Rich Smith	This Just In: Upgrades and Downgrades Big Pharma stocks get a thumbs up from UBS.
The Motley Fool October 5, 2011 Dan Caplinger	Has Teva Pharmaceutical Become the Perfect Stock? Teva still looks poised to stay near perfection for the indefinite future.
The Motley Fool July 15, 2011	Piper Jaffray Earnings Preview Piper Jaffray will unveil its latest earnings on Wednesday, July 20.
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool November 8, 2005 Stephen D. Simpson	Teva Is No Generic Generics Firm Although 2005 wasn't a great year for generics on the whole, 2006 is shaping up to be pretty interesting for Teva. Is it time to buy these shares?
The Motley Fool May 7, 2009 Rich Smith	This Just In: Upgrades and Downgrades When two analysts rated American Eagle Outfitters a buy, why did Mr. Market initially shrug, only to then drop the stock through the floor?
The Motley Fool March 5, 2009 Rich Smith	This Just In: Upgrades and Downgrades Piper loves the Pre -- and Palm.
The Motley Fool August 1, 2005 Stephen D. Simpson	Teva: Built to Last? Israeli generics giant Teva Pharmaceuticals is a high-quality company trading at a level that should still provide patient investors with solid long-term performance.
The Motley Fool May 12, 2011 Brian Orelli	Teva's Mixed Bag Diversification sure helps.
The Motley Fool May 20, 2010 Rich Smith	This Just In: Upgrades and Downgrades Standpoint Research has just taken the "unprecedented during our seven years in business" move of recommending five stocks at once, all on a single day: Accenture... Dell... Hewlett-Packard... Teva... Xerox...
The Motley Fool April 25, 2011 Sean Williams	Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing.
The Motley Fool October 13, 2009 Dave Mock	A Big Upgrade for Teva Pharmaceutical This bullish call comes from more than just one analyst.
The Motley Fool February 13, 2008 Brian Orelli	Teva Tears It Up After a stellar 2006 because of exclusive launches of some big-time generics, it seemed like Teva Pharmaceuticals would have a heck of a time keeping the pace up in 2007. Apparently, that fear was unwarranted.
The Motley Fool August 12, 2010 Jordan DiPietro	7 Burned-Out Drug Stocks These 5-star drug stocks have been beaten down to attractive levels.
The Motley Fool February 15, 2005 Stephen D. Simpson	Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
The Motley Fool November 3, 2010 Brian Orelli	Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits.
The Motley Fool April 7, 2010 Rick Steier	Is Teva Pharmaceutical a Forever Hold? Teva is a compelling reason why investors should look abroad for opportunity.
The Motley Fool May 7, 2008 Brian Orelli	Teva's on a Tear The generic-drug maker can't be stopped.
The Motley Fool September 22, 2009 Robert Steyer	Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge.
The Motley Fool May 5, 2009 Brian Orelli	Generic Growth, Acquisition Style Sales at Teva Pharmaceuticals were up 22% year over year, but don't bust out the champagne just yet.
The Motley Fool June 28, 2011 Eric Bleeker	Where Is Teva Pharmaceuticals Finding Growth? Teva should see its sales continue to climb, especially in already booming international markets.
The Motley Fool August 8, 2006 Stephen D. Simpson	Nothing Generic About Teva's Performance Once again, buying this this Israeli generics giant on dips returns a tidy profit.
The Motley Fool May 3, 2011 Brian Orelli	Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.
The Motley Fool August 6, 2011 Sean Williams	10 Large Caps to Rule Them All There's nothing generic about this company. For the inaugural large-cap pick, I think we should revisit pharma's most impervious pipeline, Teva Pharmaceuticals.
The Motley Fool May 3, 2007	Teva Pharmaceutical Has Strong Quarter: Fool by Numbers The pharmaceutical released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool February 28, 2011 Cindy Johnson	Medicis Pharmaceutical Shares Popped: What You Need to Know Medicis Pharmaceutical Corporation popped 26% in intraday trading today after reporting an inline quarter and announcing a licensing agreement with Teva Pharmaceutical Industries.
The Motley Fool August 30, 2011 Rich Smith	Piper Leads Tech Investors to Profits In a wide-ranging report released yesterday, Piper Jaffray argues forcefully that there's a "fourth wave" of computing afoot today.
The Motley Fool May 10, 2006 Stephen D. Simpson	Time to Make Room for Teva? This might be a rare chance to pick up a dominant company at an attractive price. Investors, take note.
The Motley Fool July 30, 2008 Brian Orelli	Teva Has Revenue in All the Wrong Places Sometimes double-digit growth isn't all it's cracked up to be. For generic-drug maker Teva Pharmaceuticals, the growth wasn't quite as exciting as the company's top line might suggest.
The Motley Fool July 28, 2009 Brian Orelli	All Growth, All the Time This generic-drug maker is no value play.
The Motley Fool February 17, 2010 Brian Orelli	This Is Not Your Generic Cash Production Teva's generating cash and knows how to use it.
The Motley Fool July 1, 2009	3 Stocks Hitting High Notes These stocks have hit new highs. Take a look at: Teva Pharmaceutical... Air Transport Services... STEC, Inc. ...
The Motley Fool June 6, 2005 Stephen D. Simpson	"Bad News" for Teva? Yawn... Be ready to act when the market overreacts. For those investors who think that Teva Pharmaceutical will maintain its top-dog status in the generics world, this is just a blip on the scope and/or the opportunity to build a position.
The Motley Fool May 5, 2010 Brian Orelli	Teva's Double-Edged Sword Nice quarter, but where will future growth come from?
The Motley Fool July 24, 2009	3 Stocks Hitting High Notes These stocks have reached 52-week highs. Take a look at: Wipro... Teva... AECOM...
The Motley Fool June 11, 2009	3 Stocks Hitting High Notes These stocks are reaching for the stars, hitting 52-week highs. Take a look at: HDFC Bank Limited... Teva Pharmaceutical... TiVo, Inc. ...
The Motley Fool July 14, 2008 Brian Orelli	Teva Gets a Taste of Its Own Medicine Momenta Pharmaceuticals and Novartis are challenging the patents on Teva Pharmaceutical's blockbuster multiple sclerosis drug Copaxone.
The Motley Fool November 29, 2010 Seth Jayson	Here's How Teva Pharmaceutical May Be Failing You Here's the margin picture for Teva Pharmaceutical over the past few years.
The Motley Fool November 8, 2006 Brian Lawler	Teva Is Rolling in Cash Again Investors, the bottom line is that with 13 proprietary drugs in phase 2 trials or later for some very large indications, plus 144 applications to sell generic versions of branded drugs waiting at the FDA, Teva's near-term future is strong.
The Motley Fool June 23, 2010 Rich Smith	This Just In: Upgrades and More Upgrades When clothing retailer Express returned to the Nasdaq last month, the stock promptly plunged. Debuting at $17 a share, the stock bottomed out near $13 a stub a few weeks back. But ever since, it has been flying.
The Motley Fool June 10, 2011 Matt Koppenheffer	Could Teva Pharmaceutical Score You 100% Returns? Is it high time to add Teva's stock to your portfolio?
The Motley Fool November 5, 2004 Roger Nusbaum	The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy.
The Motley Fool February 23, 2005 Bill Mann	Analyst Games at Overstock What if you could make trades on last night's prices? Well, you can't, but analyst research might pretend you can, as this Jan. 27 Overstock.com downgrade shows.
The Motley Fool July 8, 2008 Brian Orelli	Not Teva's Forte Teva Pharmaceutical's Copaxone for multiple sclerosis fails to show a benefit at double strength. Investors take note.
The Motley Fool November 2, 2010 Travis Hoium	Momenta Pharmaceuticals Shares Plunged: What You Need to Know Momenta Pharmaceuticals shares fell 10% in trading early Tuesday after Teva Pharmaceutical Industries said it expects FDA approval this year on a drug to compete with Momenta's enoxaparin.